



Clinical manifestations, risk factors, and maternal
and perinatal outcomes of coronavirus disease 2019
in pregnancy
PregCOV-19 Living Systematic Review Consortium; Allotey, John; Stallings, Elena; Bonet,
Mercedes; Yap, Magnus; Chatterjee, Shaunak; Kew, Tania; Debenham, Luke; Llavall, Anna
Clavé; Dixit, Anushka; Zhou, Dengyi; Balaji, Rishab; Lee, Siang Ing; Qiu, Xiu; Yuan,





Creative Commons: Attribution-NonCommercial (CC BY-NC)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
PregCOV-19 Living Systematic Review Consortium, Allotey, J, Stallings, E, Bonet, M, Yap, M, Chatterjee, S,
Kew, T, Debenham, L, Llavall, AC, Dixit, A, Zhou, D, Balaji, R, Lee, SI, Qiu, X, Yuan, M, Coomar, D, Sheikh, J,
Lawson, H, Ansari, K, Van Wely, M, Van Leeuwen, E, Kostova, E, Kunst, H, Khalil, A, Tiberi, S, Brizuela, V,
Broutet, N, Kara, E, Kim, CR, Thorson, A, Escuriet, R, Oladapo, OT, Mofenson, L, Zamora, J & Thangaratinam,
S 2021, 'Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019
in pregnancy: living systematic review and meta-analysis', BMJ, vol. 370, m3320.
https://doi.org/10.1136/bmj.m3320
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 11. May. 2021
the bmj | BMJ 2020;370:m3320 | doi: 10.1136/bmj.m3320 1
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AbstrAct
Objective
To determine the clinical manifestations, risk factors, 
and maternal and perinatal outcomes in pregnant and 
recently pregnant women with suspected or confirmed 
coronavirus disease 2019 (covid-19).
Design
Living systematic review and meta-analysis.
Data sOurces
Medline, Embase, Cochrane database, WHO COVID-19 
database, China National Knowledge Infrastructure 
(CNKI), and Wanfang databases from 1 December 
2019 to 6 October 2020, along with preprint servers, 
social media, and reference lists.
stuDy selectiOn
Cohort studies reporting the rates, clinical 
manifestations (symptoms, laboratory and 
radiological findings), risk factors, and maternal and 
perinatal outcomes in pregnant and recently pregnant 
women with suspected or confirmed covid-19.
Data extractiOn
At least two researchers independently extracted the 
data and assessed study quality. Random effects 
meta-analysis was performed, with estimates pooled 
as odds ratios and proportions with 95% confidence 
intervals. All analyses will be updated regularly.
results
192 studies were included. Overall, 10% (95% 
confidence interval 7% to 12%; 73 studies, 67 271 
women) of pregnant and recently pregnant women 
attending or admitted to hospital for any reason 
were diagnosed as having suspected or confirmed 
covid-19. The most common clinical manifestations 
of covid-19 in pregnancy were fever (40%) and 
cough (41%). Compared with non-pregnant women 
of reproductive age, pregnant and recently pregnant 
women with covid-19 were less likely to have 
symptoms (odds ratio 0.28, 95% confidence interval 
0.13 to 0.62; I2=42.9%) or report symptoms of fever 
(0.49, 0.38 to 0.63; I2=40.8%), dyspnoea (0.76, 0.67 
to 0.85; I2=4.4%) and myalgia (0.53, 0.36 to 0.78; 
I2=59.4%). The odds of admission to an intensive 
care unit (odds ratio 2.13, 1.53 to 2.95; I2=71.2%), 
invasive ventilation (2.59, 2.28 to 2.94; I2=0%) and 
need for extra corporeal membrane oxygenation (2.02, 
1.22 to 3.34; I2=0%) were higher in pregnant and 
recently pregnant than non-pregnant reproductive 
aged women. Overall, 339 pregnant women (0.02%, 
59 studies, 41 664 women) with confirmed covid-19 
died from any cause. Increased maternal age (odds 
ratio 1.83, 1.27 to 2.63; I2=43.4%), high body mass 
index (2.37, 1.83 to 3.07; I2=0%), any pre-existing 
maternal comorbidity (1.81, 1.49 to 2.20; I2=0%), 
chronic hypertension (2.0, 1.14 to 3.48; I2=0%), 
pre-existing diabetes (2.12, 1.62 to 2.78; I2=0%), 
and pre-eclampsia (4.21, 1.27 to 14.0; I2=0%) were 
associated with severe covid-19 in pregnancy. In 
pregnant women with covid-19, increased maternal 
age, high body mass index, non-white ethnicity, any 
pre-existing maternal comorbidity including chronic 
hypertension and diabetes, and pre-eclampsia 
were associated with serious complications such 
as admission to an intensive care unit, invasive 
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WhAt is AlreAdy knoWn on this topic
Pregnant women are considered to be a high risk group for severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential 
adverse effects of the virus on maternal and perinatal outcomes are of concern
In non-pregnant populations admitted to hospital with coronavirus disease 
2019 (covid-19) the most common symptoms are fever, cough, and dyspnoea, 
reported in more than two thirds of individuals
Advancing age, high body mass index, non-white ethnicity, and pre-existing 
comorbidities are risk factors for severe covid-19 in the general population
WhAt this study Adds
Pregnant and recently pregnant women with covid-19 diagnosed in hospital are 
less likely to have or manifest symptoms of fever, dyspnoea, and myalgia than 
non-pregnant women of reproductive age 
Pregnant and recently pregnant women are at increased risk of admission to an 
intensive care unit, receiving invasive ventilation and extra corporeal membrane 
oxygenation treatment, compared with non-pregnant women of reproductive age 
Risk factors for severe covid-19 in pregnancy include increasing maternal age, 
high body mass index, non-white ethnicity, pre-existing comorbidities, and 
pregnancy specific disorders such as gestational diabetes and pre-eclampsia 
Pregnant women with covid-19 are more likely to experience preterm birth and 
their neonates are more likely to be admitted to a neonatal unit
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ventilation and maternal death. Compared to pregnant 
women without covid-19, those with the disease had 
increased odds of maternal death (odds ratio 2.85, 
1.08 to 7.52; I2=0%), of needing admission to the 
intensive care unit (18.58, 7.53 to 45.82; I2=0%), and 
of preterm birth (1.47, 1.14 to 1.91; I2=18.6%). The 
odds of admission to the neonatal intensive care unit 
(4.89, 1.87 to 12.81, I2=96.2%) were higher in babies 
born to mothers with covid-19 versus those without 
covid-19.
cOnclusiOn
Pregnant and recently pregnant women with covid-19 
attending or admitted to the hospitals for any reason 
are less likely to manifest symptoms such as fever, 
dyspnoea, and myalgia, and are more likely to be 
admitted to the intensive care unit or needing invasive 
ventilation than non-pregnant women of reproductive 
age. Pre-existing comorbidities, non-white ethnicity, 
chronic hypertension, pre-existing diabetes, high 
maternal age, and high body mass index are risk 
factors for severe covid-19 in pregnancy. Pregnant 
women with covid-19 versus without covid-19 
are more likely to deliver preterm and could have 
an increased risk of maternal death and of being 
admitted to the intensive care unit. Their babies are 




This article is a living systematic review that will 
be updated to reflect emerging evidence. Updates 
may occur for up to two years from the date of 
original publication. This version is update 1 of the 
original article published on 1 September 2020 (BMJ 
2020;370:m3320), and previous updates can be 
found as data supplements (https://www.bmj.com/
content/370/bmj.m3320/related#datasupp). When 
citing this paper please consider adding the update 
number and date of access for clarity.
introduction
Since the first report (December 2019) of the novel 
coronavirus disease 2019 (covid-19) caused by 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), the number of confirmed cases and 
associated mortality and morbidity have increased 
rapidly.1 2 Pregnant women are considered a high 
risk group because of concerns about the effect of 
covid-19 on them during and after pregnancy, and 
on their neonates.3 Quantification of the rates of 
covid-19, its risk factors, clinical manifestations, and 
outcomes is key to planning clinical maternal care and 
management in an evolving pandemic scenario.4
Publications on covid-19 in pregnancy have risen 
steeply through individual case reports, case series, 
observational studies, and systematic reviews. Since 
the publication of our first version of the living 
systematic review on covid-19 in pregnancy,5 over 
150 reviews have been published in this area,6-11 with 
many more registered in PROSPERO.9 12 Early reviews 
mostly included case reports and case series that were 
often inappropriately meta-analysed providing biased 
estimates.13 Subsequent reviews differed little from 
each other, often including similar primary studies, 
many with duplicate data. These reviews became 
quickly outdated as new evidence emerged. Moreover, 
the sampling frames in primary studies have varied, 
ranging from universal SARS-CoV-2 testing for all 
pregnant women admitted to hospital14 15 to symptom 
based testing.16 17 Testing strategies have also differed 
within and between countries, with diagnosis in 
many early studies based on epidemiological risk 
assessment and clinical features without confirmed 
SARS-CoV-2 infection, which need to be considered in 
the analysis.18 Limitations in the external and internal 
validity of studies make it challenging for guideline 
developers and policy makers to make evidence based 
recommendations for the management of pregnant 
and recently pregnant women with covid-19.
We started this living systematic review in April 2020 
to determine the clinical manifestations of covid-19 in 
pregnant and recently pregnant women, identify the 
risk factors for complications, and quantify maternal 
and perinatal outcomes. The systematic review is being 
updated on a regular basis.
Methods
Our systematic review is based on a prospectively 
registered protocol (PROSPERO CRD42020178076; 
registered 22 April 2020)19 to evaluate a series of 
research questions on covid-19 during and after 
pregnancy. We report our findings on the rates, 
clinical manifestations, risk factors, and maternal and 
perinatal outcomes in women with covid-19 in line with 
the preferred reporting items for systematic reviews 
and meta-analyses (PRISMA) recommendations (see 
appendix 1). As more relevant data become availa-
ble, we shall address the research questions in 
our published protocol.20 Each cycle of our living 
systematic review involves weekly search updates 
(rounds), with analysis performed every 2-4 months 
for reporting through a dedicated website, with early 
analysis if new definitive evidence emerges. We are 
regularly reviewing the planned frequency of updates.
literature search
For the first publication of the review, we performed 
a systematic search of major databases: Medline, 
Embase, Cochrane database, WHO (World Health 
Organization) COVID-19 database, China National 
Knowledge Infrastructure (CNKI), and Wanfang data-
bases from 1 December 2019 to 26 June 2020 for 
relevant studies on covid-19 in pregnant and recently 
pregnant women.5 For this first update of the review, we 
searched databases up to 6 October 2020. To identify 
potential studies, we coordinated our search efforts 
with the Evidence for Policy and Practice Information 
and Co-ordinating Centre (EPPI-Centre), the WHO 
Library, and the Cochrane Gynaecology and Fertility 
group. Additional searches were conducted of preprint 
servers, blogs, websites that serve as repositories 
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for covid-19 studies, social media, guidelines, and 
reference lists of included studies and unpublished 
data. We also searched the Living Overview of the 
Evidence (LOVE) platform from June 2020.21 We 
contacted established groups that were coordinating 
or conducting surveillance and studies in pregnant 
women with covid-19, such as the WHO Maternal, 
Newborn, Child and Adolescent health (MNCAH) 
covid-19 research network, the International Network 
of Obstetric Survey Systems (INOSS), the United States 
Centers for Disease Control and Prevention (CDC), 
and the European Centre for Disease Prevention and 
Control for information on published and upcoming 
data. No language restrictions were applied. Appendix 
2 provides details of the search strategies and 
databases searched.
study selection
Two reviewers independently selected studies using 
a two stage process: they first screened the titles 
and abstracts of studies and then assessed the full 
text of the selected studies in detail for eligibility. A 
total of 10 reviewers contributed to study selection. 
Disagreements were resolved through discussion 
with a third reviewer (ST or JA). We excluded studies 
if the duplicated data for all outcomes of interest were 
published elsewhere, as reported by the study authors, 
or when the characteristics of the mother or neonate 
matched the setting, characteristics, and duration of 
another study from the same geographical location. 
When we suspected an overlap of data between 
studies, the study that provided comparative data was 
included. If there was an overlap of data or suspicion 
of duplicates of participants in studies between the 
previous and current versions of the living systematic 
review, we included studies based on their study design 
(prioritising comparative cohorts), and sample size 
(larger study prioritised). When there was uncertainty 
about duplicate data, we contacted the authors of 
primary studies. 
We defined women as having confirmed covid-19 
if they had laboratory confirmation of SARS-CoV-2 
infection irrespective of clinical signs and symptoms.22 
Women with a diagnosis based only on clinical or 
radiological findings were defined as having suspected 
covid-19. The recently pregnant group comprised 
women in the postpartum and post-abortion period. We 
included studies that compared covid-19 rates, clinical 
manifestations (symptoms, laboratory and radiological 
results), risk factors, and associated mortality and 
morbidity between pregnant and recently pregnant 
and non-pregnant women of reproductive age, and 
those that compared maternal and perinatal outcomes 
in pregnant women with and without covid-19. In 
studies comparing maternal and perinatal outcomes 
of pregnant women with covid-19 to those without, we 
classified the comparative controls as being historical 
if the cohort of pregnant women without covid-19 
were pregnant before December 2019. Studies on non-
comparative cohorts with a minimum of 10 participants 
were included if they reported on the rates and clinical 
manifestations of covid-19 and relevant outcomes in 
pregnant and recently pregnant women. We defined 
cohort studies as those that sampled participants on 
the basis of exposure, followed-up participants over 
time, and ascertained the outcomes.23 The PROSPERO 
protocol provides a full list of the risk factors, clinical 
features, and outcomes evaluated.19
The sampling frames for detecting covid-19 included 
universal screening and testing, when all women were 
assessed for covid-19 using reverse transcriptase 
polymerase chain reaction (RT-PCR) for SARS-CoV-2 
or chest computed tomography; risk based testing 
on the basis of epidemiological history and clinical 
manifestations by National Health Commission of 
China (NHCC) guidelines18; and symptom based when 
testing was performed on women with symptoms and 
those with a history of contact with affected individuals. 
We defined the population as being selected when 
only specific groups of women were included, such 
as those undergoing caesarean section or in the third 
trimester. We categorised studies as a high risk group if 
only women with any pre-existing medical or obstetric 
risk factors were included, low risk if women did not 
have any risk factors, and any risk if all women were 
included.
study quality assessment and data extraction
The quality of the comparative cohort studies was 
assessed for selection, comparability, and outcome 
ascertainment bias using the Newcastle Ottawa 
scale.24 Studies achieving four stars for selection, two 
for comparability, and three for ascertainment of the 
outcome were considered to have a low risk of bias. 
Studies achieving two or three stars for selection, one 
for comparability, and two for outcome ascertainment 
were considered to have a medium risk of bias, 
and any study achieving one star for selection or 
outcome ascertainment, or zero for any of the three 
domains, was regarded as having a high risk of bias. 
We assessed the quality of studies reporting on the 
prevalence of clinical manifestations or outcomes for 
internal and external validity using an existing tool.25 
The following were considered as low risk of bias for 
external validity: representative of national population 
for relevant variables (population), representative of 
target population (sampling frame), random selection 
(selection bias), and more than 75% response rate 
in individuals with and without the outcome (non-
response bias).25 Two independent reviewers extracted 
data using a pre-piloted form.
statistical analysis
We pooled the comparative dichotomous data using 
random effects meta-analysis and summarised 
the findings as odds ratios with 95% confidence 
intervals. To combine comparative continuous data 
with dichotomous data we transformed standardised 
mean differences to logarithm odds ratios, assuming 
a normal underlying distribution.26 We pooled the 
dichotomous non-comparative data for rates of clinical 
manifestations and maternal and perinatal outcomes 
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as proportions with 95% confidence intervals using 
Dersimonian and Laird random effects meta-analysis 
after transforming data using Freeman-Tukey double 
arcsin transformation. Heterogeneity was reported 
as I2 statistics. We undertook subgroup analysis by 
country status (high income v low and middle income), 
sampling frame (universal, risk based, and symptom 
based testing, including not reported), and risk status 
of women in the studies (high, low, any). Sensitivity 
analysis was performed by restricting the analysis 
to women with confirmed covid-19, study quality 
(high, low), and population (unselected, selected). All 
analyses were done with Stata (version 16).
Patient and public involvement
The study was supported by Katie’s Team, a dedicated 
patients and public involvement group in Women’s 
Health. The team was involved in the conduct, 
interpretation, and reporting of this living systematic 
review through participation in virtual meetings.
results
In the original review, 20 625 unique citations were 
identified after removing duplicates from 49 684 
citations, with 77 cohort studies included in the review.5 
After removing duplicates from 130 861 citations, 
24 281 unique citations were identified and 192 cohort 
studies (131 comparative, 61 non-comparative) were 
included in this update of the systematic review (fig 
1). Two studies included in the original systematic 
review were excluded from the update because the 
information reported in those studies were reported in 
more recent and larger studies.27 28
characteristics of included studies
Of 192 studies, 58 (30%) were from the United 
States; 31 from China (16%); 17 from Italy; 15 from 
Spain; eight from Turkey; seven each from the United 
Kingdom and India; five each from Brazil, France, and 
Mexico; three each from Iran and Portugal; two each 
from Belgium, Denmark, the Netherlands, Peru, and 
Sweden; and one each from Bangladesh, Chile, Estonia, 
Israel, Japan, Germany, Ireland, Kuwait, Pakistan, 
Qatar, Romania, Russia, and Switzerland. Most studies 
tested respiratory samples using RT-PCR to confirm 
the presence of SARS-CoV-2 (97%, 187/192); five 
studies tested for SARS-CoV-2 antibodies to confirm 
the diagnosis of covid-19; 43 studies additionally 
diagnosed covid-19 based only on clinical suspicion. 
Fourteen studies (602 565 women) compared pregnant 
populations with non-pregnant populations,29-42 
and 47 studies (26 017 women) compared pregnant 
women with covid-19 versus pregnant women without 
covid-19.43-89 Eighty two cohort studies reported on 
clinical manifestations (41 396 pregnant, 434 348 
non-pregnant women), 92 studies reported on covid-19 
related maternal outcomes (49 443 pregnant, 568 386 
non-pregnant women), and 95 studies reported on 
pregnancy related maternal (54 943 women) and 
perinatal outcomes (9466 neonates) (see appendix 
3). The sampling frames included universal testing 
(89 studies), risk based NHCC guidelines (25 studies), 
and symptom based (32 studies) strategies. Forty six 
studies did not report the sampling strategy.
Quality of included studies
Overall, 56% (73/131) of the comparative cohort 
studies evaluated using the Newcastle Ottawa scale 
had an overall low risk of bias (see appendix 4a). 
Most (93%, 122/131) had a low risk of bias for study 
selection and nine (7%) had a medium risk. The risk of 
bias for comparability of cohorts was low in 59 of the 
studies (45%), medium in 71 (54%), and high in one 
(1%). For outcome assessment of the cohorts, 47 (36%) 
studies had a low risk of bias, 82 (63%) a medium risk, 
and two (2%) a high risk. Quality assessment of the 
prevalence studies for external validity showed a low 



























Electronic databases from inception to 13 October 2020





(64 676 pregnant and recently pregnant women with covid-19;
569 981 non-pregnant reproductive aged women with covid-19)
Prevalence of covid-19 (73 studies)
Risk factors for covid-19 and complications (108 studies)
Clinical manifestations of covid-19 (82 studies)
Covid-19 related outcomes (92 studies)
Pregnancy related maternal and perinatal outcomes (95 studies)
1842
192
Fig 1 | study selection process. *twitter, national reports, blog by j thornton, Obg 
Project, cOviD-19 and Pregnancy cases, www.obgproject.com/2020/04/07/covid-19-
research-watch-with-dr-jim-thornton/; ePPi-centre, cOviD-19: a living systematic map 
of evidence, http://eppi.ioe.ac.uk/cms/Projects/DepartmentofHealthandsocialcare/
Publishedreviews/cOviD-19livingsystematicmapoftheevidence/tabid/3765/
Default.aspx; norwegian institute of Public Health, niPH systematic and living map 
on cOviD-19 evidence, www.nornesk.no/forskningskart/niPH_mainmap.html; 
johns Hopkins university center for Humanitarian Health; cOviD-19, maternal and 
child Health, nutrition, http://hopkinshumanitarianhealth.org/empower/advocacy/
covid-19/covid-19-children-and-nutrition/; researchgate, cOviD-19 research 
community, www.researchgate.net/community/cOviD-19; and living Overview 
of the evidence, coronavirus disease (cOviD-19), https://app.iloveevidence.com/
loves/5e6fdb9669c00e4ac072701d?population=5d062d5fc80dd41e58ba8459
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the studies, sampling in 30% (57/192), selection in 
82% (157/192), and non-response in 99% (191/192). 
For internal validity, there was low risk of bias for 
data collection in 96% (184/192) of the studies, case 
definition in 56% (108/192), measurement in 98% 
(189/192), differential verification in 95% (182/192), 
adequate follow-up in 35% (67/192), and appropriate 
numerator and denominator in 92% (177/192) (see 
appendix 4b).
rates of covid-19 in pregnant and recently pregnant 
women
The overall rate of covid-19 diagnosis in pregnant 
and recently pregnant women attending or admitted 
to hospital for any reason was 10% (95% confidence 
interval 7% to 12%; 73 studies, 67 271 women; fig 2 
and fig 3). Rates varied by sampling strategy: of the 
women sampled by universal screening, 7% (5% to 
8%; 60 studies, 57 144 women) were diagnosed as 
having covid-19 compared with 28% (15% to 43%; 11 
studies, 2436 women) of women sampled on the basis 
of symptoms. Most studies with a prevalence rate for 
covid-19 greater than 15% were from the US, except 
for two studies from the UK, and one each from Mexico, 
Turkey, France, and Iran.90-95 One in 20 asymptomatic 
women (4%, 3% to 7%; 26 studies) attending or 
admitted to hospital had a diagnosis of covid-19 (see 
appendix 5a). Three quarters (73%, 62% to 82%; 38 
studies) of the 906 pregnant women with covid-19 in 
the universal screening population were asymptomatic 
(see appendix 5b). Non-white ethnicity was associated 
with a diagnosis of covid-19 in pregnancy (odds ratio 
1.66, 95% confidence interval 1.01 to 2.72; 11 studies; 
8691 women); none of the other maternal factors 
assessed were associated with a diagnosis of covid-19 
in pregnant women (see appendix 6a).
clinical manifestations of covid-19 during 
pregnancy and after delivery
The most common symptoms reported by pregnant 
and recently pregnant women with suspected or 
confirmed covid-19 were fever (40%) and cough 
(41%); raised white cell count (26%), lymphopaenia 
(33%) and raised C reactive protein levels (49%) 
were the most common laboratory findings (fig 4). 
Compared with non-pregnant women of reproductive 
age with covid-19, pregnant and recently pregnant 
women with the disease were less likely to have 
symptoms (odds ratio 0.28, 95% confidence interval 
0.13 to 0.62; 4 studies; 462 051 women), or manifest 
symptoms of fever (0.49, 0.38 to 0.63; 11 studies, 
240 324 women), dyspnoea (0.76, 0.67 to 0.85; 11 
studies; 240 324 women) and myalgia (0.53, 0.36 
to 0.78; 8 studies, 240 105 women) (fig 5). Pregnant 
women with covid-19 had increased body mass index 
compared to non-pregnant women with the disease 
(1.98, 1.74 to 2.26; 2 studies, 461 897 women), 
and were more likely to have pre-existing diabetes 
(1.35, 1.24 to 1.46; 5 studies, 462 262 women) (see 
appendix 6b). Sensitivity analysis restricted to various 
sampling frames showed lower estimates of reported 
symptoms in the universal screening population and 
higher estimates of fever, cough, and dyspnoea in the 
symptom-based population (see appendix 7). The rates 
of clinical manifestations varied when the analysis 
was restricted to only women with RT-PCR confirmed 
covid-19, unselected populations, and women with 
any risk (see appendix 7).
Outcomes related to covid-19 in pregnant and 
recently pregnant women
Overall, 339 pregnant women (59 studies, 41 664 
women) with confirmed covid-19 died from any cause 
(0.02%, 95% confidence interval 0.00% to 0.42%). 
Severe covid-19 infection as defined by the authors, 
was diagnosed in 10% (6% to 15%; 39 studies, 5621 
women) of pregnant and recently pregnant women 
with suspected or confirmed covid-19; 4% (2% to 
7%; 50 studies, 41 288 women) of pregnant women 
with covid-19 were admitted to an intensive care unit, 
3% (1% to 5%; 31 studies, 42 026 women) required 
invasive ventilation, and 0.2% (0.0% to 0.7%; 13 
studies, 33 521 women) required extracorporeal 
membrane oxygenation (ECMO) (fig 4). Appendix 
8 provides the rates of complications by sampling 
strategy. Compared with non-pregnant women of 
reproductive age with covid-19, the odds of admission 
to the intensive care unit (odds ratio 2.13, 95% 
confidence interval 1.53 to 2.95; seven studies, 601 
108 women) and need for invasive ventilation (2.59, 
2.28 to 2.94; six studies, 601 044 women) and ECMO 
(2.02, 1.22 to 3.34; two studies, 461 936 women) 
were higher in pregnant and recently pregnant women 
(table 1). 
Maternal risk factors associated with severe covid-19 
were increasing age (odds ratio 1.83, 95% confidence 
interval 1.27 to 2.63; seven studies, 3561 women), 
high body mass index (2.37, 1.83 to 3.07; five studies, 
3367 women), any pre-existing maternal comorbidity 
(1.81, 1.49 to 2.20; 3 studies; 2634 women), chronic 
hypertension (2.0, 1.14 to 3.48; two studies, 858 
women), pre-eclampsia (4.21, 1.27 to 14.0; 4 studies; 
274 women), and pre-existing diabetes (2.12, 1.62 
to 2.78; 3 studies, 3333 women) (fig 6). Increasing 
maternal age (2.11, 1.69 to 2.63; 7 studies, 31 710 
women), high body mass index (2.71, 1.10 to 6.63; 4 
studies, 31 456 women), non-white ethnicity (1.66, 
1.20 to 2.29; 4 studies, 31 543 women), pre-existing 
maternal comorbidity (1.70, 1.34 to 2.15; 5 studies, 
31 512 women), chronic hypertension (4.72, 2.37 to 
9.41; 5 studies, 31 433 women), pre-existing diabetes 
(4.67, 1.94 to 11.22; 6 studies, 31 473 women), and 
gestational diabetes (3.27, 1.55 to 6.89; 2 studies, 
777 women), were associated with admission to 
an intensive care unit. Risk factors associated with 
maternal death and the need for invasive ventilation 
included: non-white ethnicity (1.61, 1.05 to 2.47; 3 
studies, 31 469 women; 2.23, 1.25 to 3.97; 1 study, 
669 women; respectively), and high body mass index 
(2.27, 1.20 to 4.31; 3 studies, 31 085 women; 6.61, 
1.98 to 22.02; 2 studies, 485 women; respectively; 
table 2).
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Universal screening
  Vintzileos W 2020
  Tassis B 2020
  Khalil A 2020
  Gagliardi L 2020
  Naqvi M 2020
  Ceulemans D 2020
  Miller E 2020
  Doria M 2020
  London V 2020
  Bianco A 2020
  Goldfarb IT 2020
  LaCourse S 2020
  Ochiai D 2020
  Freiesleben N 2020
  Cosma S 2020
  Crovetto F 2020
  Fassett MJ  2020
  Blitz M (2) 2020
  Santos RR 2020
  Khalil A (2) 2020
  Berkowitz KM 2020
  Ferrazzi E (2) 2020
  Adeysuriya S 2020
  Flannery DD 2020
  Yassa M (2) 2020
  Dodesini AR 2020
  Nayak AH 2020
  Salvatore CM 2020
  Huerta Saenz IH 2020
  Cronin S 2020
  Emeruwa U (1) 2020
  Sakowicz A 2020
  Maru S 2020
  Llorca J 2020
  Massarotti C 2020
  Youssef A 2020
  Blitz MJ (3) 2020
  Farghaly MAA 2020
  Franchi M (2) 2020
  Zollkau J 2020
  Zaharie G 2020
  Egerup P 2020
  Cubo AM 2020
  Mattern J 2020
  Pineles BJ 2020
  Ruggiero M 2020
  Kalafat E (1) 2020
  Veerus P 2020
  Encinas Pardilla MB 2020
  Cavaliere AF 2020
  Kelly JC (1) 2020
  Ahlberg M 2020
  Waghmare R 2020
  ROI covid 19 Update 2020
  Vinuela MC 2020
  Haizler-Cohen L 2020
  Diaz-Corvillon P 2020
  Wang M 2020
  Ahmed I (2) 2020
  Malhotra Y (1) 2020
Subtotal: I2=98.0%,P=0.00
0.20 (0.14 to 0.27)
0.02 (0.01 to 0.06)
0.07 (0.04 to 0.13)
0.01 (0.00 to 0.02)
0.01 (0.00 to 0.07)
0.03 (0.02 to 0.05)
0.04 (0.02 to 0.05)
0.12 (0.07 to 0.19)
0.13 (0.07 to 0.23)
0.15 (0.10 to 0.22)
0.03 (0.02 to 0.04)
0.03 (0.01 to 0.06)
0.04 (0.01 to 0.13)
0.03 (0.02 to 0.04)
0.10 (0.07 to 0.15)
0.14 (0.12 to 0.17)
0.00 (0.00 to 0.01)
0.19 (0.15 to 0.23)
0.00 (0.00 to 0.02)
0.01 (0.01 to 0.02)
0.02 (0.01 to 0.04)
0.03 (0.02 to 0.04)
0.04 (0.02 to 0.08)
0.08 (0.06 to 0.09)
0.08 (0.05 to 0.11)
0.14 (0.04 to 0.40)
0.14 (0.12 to 0.17)
0.08 (0.07 to 0.09)
0.09 (0.06 to 0.13)
0.10 (0.05 to 0.16)
0.15 (0.12 to 0.18)
0.07 (0.06 to 0.09)
0.37 (0.29 to 0.46)
0.02 (0.01 to 0.03)
0.02 (0.01 to 0.04)
0.04 (0.01 to 0.11)
0.11 (0.10 to 0.12)
0.19 (0.12 to 0.29)
0.00 (0.00 to 0.02)
0.01 (0.00 to 0.03)
0.02 (0.01 to 0.05)
0.02 (0.02 to 0.03)
0.07 (0.05 to 0.10)
0.08 (0.05 to 0.12)
0.08 (0.07 to 0.10)
0.09 (0.06 to 0.13)
0.14 (0.11 to 0.17)
0.00 (0.00 to 0.02)
0.02 (0.02 to 0.02)
0.03 (0.01 to 0.06)
0.05 (0.03 to 0.07)
0.06 (0.05 to 0.07)
0.12 (0.11 to 0.14)
0.14 (0.11 to 0.17)
0.15 (0.09 to 0.23)
0.17 (0.15 to 0.19)
0.06 (0.05 to 0.09)
0.07 (0.05 to 0.08)
0.24 (0.20 to 0.29)
0.29 (0.25 to 0.33)


































































































































Fig 2 | Prevalence of severe acute respiratory syndrome coronavirus 2 in pregnant and recently pregnant women identified by universal screening. 
meta-analysis includes one study (liao 2020)46 screened using national Health commission china criteria with no events. round number represents 
search strategy updates in the living systematic review. Overall estimate for sampling strategies can be found in figure 3
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maternal and perinatal outcomes in pregnant and 
recently pregnant women with covid-19
In pregnant and recently pregnant women with 
covid-19 compared with pregnant and recently 
pregnant women without the disease, the odds of 
all cause mortality (odds ratio 2.85, 95% confidence 
interval 1.08 to 7.51; 8 studies, 4820 women), and 
admission to the intensive care unit (18.58, 95% 
confidence interval 7.53 to 45.82; 7 studies, 4990 
women) were higher (table 1). In pregnant and recently 
pregnant women with covid-19, the overall rate of 
preterm birth was 17% (95% confidence interval 14% 
to 19%; 70 studies, 9369 women) and of spontaneous 
preterm birth was 6% (4% to 9%; 17 studies, 1629 
women) (fig 4). Seventy two stillbirths (47 studies; 
9020 offspring) and 41 neonatal deaths (51 studies; 
8263 neonates) occurred among these women (fig 4). 
Compared to pregnant and recently pregnant women 
without the disease, pregnant women with covid-19 
were at higher risk of any preterm birth (odds ratio 1.47, 
95% confidence interval 1.14 to 1.91; 18 studies, 8549 
women) and stillbirth (2.84, 95% confidence interval 
1.25 to 6.45; 9 studies, 5794 women), although the 
overall number of stillbirth was small (only nine events 
in the covid-19 group). 
Overall, 33% (95% confidence interval 24% to 
43%; 41 studies, 3323 women) of neonates born to 
women with covid-19 were admitted to the neonatal 
intensive care unit (NICU) (fig 4), with a higher risk 
of NICU admission (odds ratio 4.89, 95% confidence 
interval 1.87 to 12.81; 10 studies, 5873 neonates) 
than neonates born to women without the disease. No 
differences were observed for other perinatal outcomes. 
Appendix 9 provides the rates of covid-19 related 
and pregnancy related outcomes for the individual 
studies.
discussion
Compared with the original version of our living 
systematic review, the findings in this update remain 
consistent for prevalence of covid-19, rates of clini-
cal manifestations, and outcomes in pregnant and 
recently pregnant women. One in 10 pregnant or 
recently pregnant women who are attending or 
admitted to hospital for any reason were diagnosed as 
having suspected or confirmed covid-19, although the 
rates vary by sampling strategy. Pregnant and recently 
pregnant women were more likely to be asymptomatic 
than non-pregnant women of reproductive age, and 
showed covid-19 related symptoms of fever, dyspnoea, 
and myalgia less often than non-pregnant women with 
covid-19. Whereas testing for SARS-CoV-2 in non-
pregnant women is based on symptoms or contact 
history, testing in pregnant women is usually done 
when they are in hospital for reasons that might not 
be related to covid-19. Pregnant or recently pregnant 
women with covid-19 seem to be at increased risk 
of requiring admission to an intensive care unit, 
invasive ventilation, and extra corporeal membrane 
oxygenation compared to non-pregnant, reproductive 
Symptom based screening
  Campbell K 2020
  Fox N 2020
  Qadri F 2020
  Duffy C 2020
  London V 2020
  LaCourse S 2020
  Griffin I 2020
  Vivanti A (1) 2020
  Antoun L 2020
  Farhat AS 2020
  Reforma LG 2020
Subtotal: I2=98.0%,P=0.00
Not known
  Gobierno de Mexico (06/06)
  Sahin D 2020
  Zhang P 2020
  Cojocaru L 2020
Subtotal: I2=99.7%,P=0.00
Overall: I2=98.97%, P=0.00
with estimated predictive interval
0.04 (0.03 to 0.06)
0.04 (0.03 to 0.06)
0.08 (0.05 to 0.13)
0.41 (0.26 to 0.57)
0.72 (0.61 to 0.80)
0.19 (0.10 to 0.33)
0.33 (0.24 to 0.44)
0.41 (0.35 to 0.48)
0.29 (0.20 to 0.40)
0.80 (0.61 to 0.91)
0.16 (0.11 to 0.23)
0.28 (0.15 to 0.43)
0.37 (0.36 to 0.38)
0.29 (0.21 to 0.39)
0.20 (0.17 to 0.25)
0.04 (0.04 to 0.05)
0.21 (0.04 to 0.47)








































Fig 3 | Prevalence of severe acute respiratory syndrome coronavirus 2 in pregnant and recently pregnant women identified by symptom based 
screening and unknown sampling strategies. meta-analysis includes one study (liao 2020)46 screened using national Health commission china 
criteria with no events. symptom based screening includes screening based on symptoms or history of contact with individuals with covid-19. round 
number represents search strategy updates in the living systematic review. Overall estimate for sampling strategies also includes prevalence data 
identified by universal screening, which are shown in figure 2
 on 30 M
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aged women with covid-19. Increased maternal age, 
high body mass index, non-white ethnicity, and pre-
existing comorbidities are associated with severe 
disease. Compared to pregnant women without 
covid-19, pregnant women with covid-19 are at 
increased risk of death, admission to the intensive 
care unit, delivering preterm, and their babies being 
admitted to the neonatal unit. The overall rates 
of stillbirth and neonatal death are low in women 
with suspected or confirmed covid-19. Substantial 
heterogeneity was observed in the estimates for rates 
of clinical manifestations and outcomes, which varied 
by sampling frames, participant selection, and risk 
status of the participants. 
This update of the living systematic review includes 
more than double the number of studies included in the 
original version, and five times more pregnant women 
with covid-19. In addition to an increase in precision of 
the estimates for previously identified risk factors (age, 
body mass index, and comorbidities such as diabetes 
and chronic hypertension) for serious complications in 
pregnant and recently pregnant women with covid-19, 
Clinical manifestations
  Symptoms
    Fever
    Cough
    Dyspnoea
    Myalgia
    Ageusia
    Diarrhoea
  Laboratory findings
    Raised WCC
    Lymphopaenia
    Thrombocytopaenia
    Abnormal LFTs
    Raised PCT
    Raised CRP
  Radiological findings
    Ground glass appearance
    Any CT abnormality
Maternal and perinatal outcomes
Clinical outcomes
  Covid-19 related outcomes
    All cause mortality
    Admission to ICU
    Severe covid-19
    Invasive ventilation
    ECMO
    Oxygen/cannula
    ARDS
    Pneumonia
    Cardiac/liver/renal failure
  Pregnancy related outcomes
    Preterm birth <37 weeks
    Spontaneous preterm birth
    PPROM <37 weeks
    Caesarean section
    Vaginal delivery
    Postpartum haemorrhage
  Offspring outcomes
    Stillbirth
    Neonatal death
    Admission to neonatal unit
    Neonatal sepsis
    Abnormal Apgar score













































































0.40 (0.31 to 0.49)
0.41 (0.33 to 0.50)
0.21 (0.15 to 0.28)
0.19 (0.12 to 0.27)
0.14 (0.06 to 0.24)
0.08 (0.06 to 0.10)
0.26 (0.14 to 0.40)
0.33 (0.25 to 0.41)
0.06 (0.02 to 0.10)
0.13 (0.06 to 0.21)
0.21 (0.00 to 0.59)
0.49 (0.36 to 0.62)
0.69 (0.46 to 0.87)
0.64 (0.47 to 0.80)
0.00 (0.00 to 0.00)
0.04 (0.02 to 0.07)
0.10 (0.06 to 0.15)
0.03 (0.01 to 0.05)
0.00 (0.00 to 0.00)
0.22 (0.12 to 0.36)
0.07 (0.01 to 0.17)
0.35 (0.26 to 0.45)
0.00 (0.00 to 0.00)
0.17 (0.14 to 0.19)
0.06 (0.04 to 0.09)
0.05 (0.03 to 0.07)
0.54 (0.49 to 0.58)
0.46 (0.42 to 0.50)
0.08 (0.03 to 0.14)
0.00 (0.00 to 0.00)
0.00 (0.00 to 0.00)
0.33 (0.24 to 0.43)
0.01 (0.00 to 0.03)
0.01 (0.00 to 0.02)
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Fig 4 | rates of clinical manifestations of coronavirus disease 2019 (covid-19) in pregnant women and recently pregnant women with suspected 
or confirmed covid-19 and associated maternal and perinatal outcomes. ecmO=extracorporeal membrane oxygenation; arDs=acute respiratory 
distress syndrome; PPrOm=preterm premature rupture of membranes; wcc=white cell count; lFt=liver function test; Pct=procalcitonin; crP=c 
reactive protein; ct=computed tomography; icu=intensive care unit
 on 30 M
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in this update, we identified additional risk factors 
such as non-white ethnicity, and potential association 
with pregnancy specific conditions such as gestational 
diabetes and pre-eclampsia, and increased risk of 
adverse outcomes in pregnant women with covid-19 
than without the disease. 
Any symptom
  Cheng B 2020
  Wei L 2020
  Wang Z 2020
  Zambrano LD 2020
Subtotal: I2=42.9%,P=0.15
Fever
  Liu F 2020
  Yin M 2020
  Qiancheng X 2020
  Cheng B 2020
  Wei L 2020
  Wang Z 2020
  Mohr-Sasson A 2020
  Xu S 2020
  Badr DA 2020
  Molteni E 2020
  Zambrano LD 2020
Subtotal: I2=40.8%,P=0.08
Cough
  Liu F 2020
  Yin M 2020
  Qiancheng X 2020
  Cheng B 2020
  Wei L 2020
  Wang Z 2020
  Xu S 2020
  Cerbulo-Vazquez A2020
  Badr DA 2020
  Molteni E 2020
  Zambrano LD 2020
Subtotal: I2=63.6%,P=0.00
Dyspnoea
  Liu F 2020
  Yin M 2020
  Qiancheng X 2020
  Cheng B 2020
  Wei L 2020
  Wang Z 2020
  Mohr-Sasson A 2020
  Xu S 2020
  Badr DA 2020
  Molteni E 2020
  Zambrano LD 2020
Subtotal: I2=4.4%,P=0.40
Myalgia
  Yin M 2020
  Cheng B 2020
  Wei L 2020
  Xu S 2020
  Cerbulo-Vazquez A2020
  Badr DA 2020
  Molteni E 2020




0.16 (0.05 to 0.54)
0.62 (0.08 to 4.92)
0.03 (0.00 to 0.56)
0.39 (0.38 to 0.41)
0.28 (0.13 to 0.62)
0.22 (0.06 to 0.85)
0.20 (0.06 to 0.66)
0.19 (0.06 to 0.57)
0.59 (0.26 to 1.37)
0.40 (0.11 to 0.77)
0.29 (0.11 to 0.77)
0.25 (0.05 to 1.18)
0.28 (0.08 to 1.00)
0.96 (0.54 to 1.71)
0.67 (0.47 to 0.95)
0.52 (0.50 to 0.50)
0.49 (0.38 to 0.63)
0.55 (0.15 to 2.05)
1.11 (0.42 to 2.93)
0.23 (0.08 to 0.63)
0.55 (0.24 to 1.27)
1.31 (0.39 to 4.47) 
0.20 (0.06 to 0.62)
0.56 (0.19 to 1.68)
1.33 (0.11 to 15.70)
1.47 (0.75 to 2.87) 
1.31 (0.83 to 2.05)
0.63 (0.61 to 0.65)
0.72 (0.50 to 1.03)
0.90 (0.05 to 15.47)
1.00 (0.33 to 3.03)
0.62 (0.12 to 3.27)
0.32 (0.11 to 0.92)
1.56 (0.09 to 26.80)
0.39 (0.04 to 3.72)
0.30 (0.06 to 1.40) 
0.52 (0.17 to 1.60)
0.57 (0.31 to 1.05)
1.10 (0.77 to 1.56)
0.75 (0.72 to 0.78)
0.76 (0.67 to 0.85)
0.52 (0.12 to 2.27)
0.30 (0.04 to 2.50)
0.49 (0.02 to 12.63)
0.63 (0.13 to 3.07)
8.00 (0.50 to 127.90)
0.24 (0.13 to 0.44)
0.83 (0.58 to 1.18)
0.50 (0.49 to 0.52)
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Fig 5 | clinical manifestations of coronavirus disease 2019 (covid-19) in pregnant and recently pregnant women compared with non-pregnant women 
of reproductive age with covid-19
 on 30 M













J: first published as 10.1136/bm
j.m







10 doi: 10.1136/bmj.m3320 | BMJ 2020;370:m3320 | the bmj
strengths and limitations of this review
In this unprecedented pandemic situation, where 
evidence is rapidly produced and published in various 
formats, our living systematic review underpinned by 
robust methods and continually updated at regular 
intervals is relevant for several reasons. Firstly, it 
addresses important research questions relevant 
to clinical decision making and policies. Secondly, 
uncertainties remain for key outcomes that require 
further evidence. Thirdly, the rapid turnover of 
evidence in various formats requires assessments of 
study quality and regular updating of the findings. 
Finally, our living systematic review is producing 
strong evidence base for living guidelines on covid-19 
and pregnancy.
We undertook a comprehensive search and 
coordinated our efforts with key organisations and 
research groups, such as WHO, the Cochrane Centre, 
and EPPI-Centre. To minimise risk of bias we restricted 
our meta-analysis to cohort studies, and we reported 
the quality of the included studies. By contacting 
the authors and obtaining reports not published in 
PubMed, we minimised the risk of missing relevant 
studies. Our systematic review has a large sample size 
and it is continuously increasing. Our living meta-
analyses framework will enable us to rapidly update 
the findings as new data emerge. We undertook 
extensive work to ensure that duplicate data are 
not included. Our various comparative analyses 
allowed us to comprehensively assess the association 
between pregnancy and covid-19 related outcomes, 
covid-19 and pregnancy outcomes, risk factors for 
SARS-CoV-2 infection, and complications. Our review 
helps to understand the variations in estimates 
through sensitivity analyses by sampling strategies, 
population characteristics, and risk factors, and it 
provides confidence in the rates of reported outcomes. 
The update has allowed us to seamlessly incorporate 
new evidence from 115 studies and more than half a 
million women, published since our original review in 
June 2020.
Our systematic review also has limitations. The 
primary studies used varied sampling frames to 
identify women with covid-19, comprised women 
with suspected and confirmed covid-19, and primarily 
reported on pregnant women who required visits to 
hospital, including for childbirth, thereby affecting 
the generalisability of the estimates. Although our 
sensitivity analyses aimed to tackle some of these 
problems, the numbers and sample sizes of the 
individual studies were too small to identify differences 
between the subgroups. The timing of assessment of 
the clinical manifestations of disease was generally 
not available. The definitions of symptoms, tests, 
and outcomes were heterogeneous. Furthermore, 
poor reporting of the criteria for caesarean section, 
admissions to the neonatal unit, and the causes 
of preterm birth, made it difficult to disentangle 
iatrogenic effect from the true impact of the disease. 
There continues to be a paucity of comparative data 
to assess the risk of pregnancy complications in 
women with and without covid-19. Studies comparing 
maternal and perinatal outcomes in pregnant women 
with covid-19 against historical cohorts of pregnant 
women, could be biased owing to differences in the 
environment in which deliveries occur. During the 
pandemic, healthcare systems have faced increased 
pressure and strain on services, with resulting effects 
on service delivery and quality of care.96 97 Lockdown 
measures, social distancing, and changes to livelihood 
have led to increased depression and anxiety, and 
reduction in physical activity and access or attendance 
table 1 | Outcomes in pregnant and recently pregnant women with coronavirus disease 2019 (covid-19)
Outcomes no of studies
women (no with event/no in group (%))
Odds ratio (95% ci) i2 (%)Pregnant women with covid-19 comparison group
comparison group: non-pregnant women of reproductive age with covid-19
All cause mortality 8 103/34 047 (0.3) 3388/567 075 (0.6) 0.96 (0.79 to 1.18) 0
ICU admission 7 616/34 035 (1.8) 9568/567 073 (1.7) 2.13 (1.54 to 2.95) 71.2
Invasive ventilation 6 270/34 001 (0.8) 3280/567 043 (0.6) 2.59 (2.28 to 2.94) 0
ECMO 2 17/30 446 (0.1) 120/431 490 (0.0) 2.02 (1.22 to 3.34) 0
Oxygen through nasal cannula 2 8/48 (16.7) 49/106 (46.2) 0.21 (0.04 to 1.13) 65.7
ARDS 1 0/17 (0) 0/26 (0) 1.51 (0.03 to 79.93) NE
Major organ failure 1 0/17 (0) 0/26 (0) 1.51 (0.03 to 79.93) NE
comparison group: pregnant women without covid-19
Maternal outcomes:
 All cause mortality 8* 8/1195 (0.7) 8/3625 (0.2) 2.85 (1.08 to 7.52) 0
 ICU admission 7* 64/1508 (4.2) 4/3482 (0.1) 18.58 (7.53 to 45.82) 0
 Preterm birth <37 weeks 18 147/1184 (12.4) 572/7365 (7.8) 1.47 (1.14 to 1.91) 18.6
 Caesarean section 21*† 669/1854 (36.1) 4221/11842 (35.6) 1.12 (0.91 to 1.38) 57.6
Perinatal outcomes:
 Stillbirth 9* 9/1039 (0.9) 26/4755 (0.5) 2.84 (1.25 to 6.45) 0
 Neonatal death 8* 4/970 (0.4) 5/3316 (0.2) 2.77 (0.92 to 8.37) 0
 Admission to neonatal unit 10* 329/1285 (25.6) 519/4588 (11.3) 4.89 (1.87 to 12.81) 96.2
 Abnormal Apgar score at 5 minutes 6 13/662 (2.0) 46/2823 (1.6) 1.38 (0.71 to 2.70) 0
 Fetal distress 2 11/77 (14.3) 13/263 (4.9) 2.37 (0.77 to 7.31) 0
ICU=intensive care unit; ECMO=extracorporeal membrane oxygenation; ARDS=acute respiratory distress syndrome; NE=not estimable.
The denominator is number of pregnancies for all outcomes.
*Includes UK Obstetric Surveillance System44 study with historical comparative cohort (694 women). 
†Includes Gulersen et al 202060 with historical comparative cohort (50 women).
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Age*
  Kayem G 2020
  Martinez-Perez O 2020
  Khoury R 2020
  Masmejan S 2020
  Menezes MO 2020
  Vigel-De Gracia P (2) 2020
  Chen L 2020 (continuous age)
Subtotal: I2=43.4%,P=0.10
Body mass index
  Kayem G 2020
  Martinez-Perez O 2020
  Khoury R 2020
  Menezes MO 2020
  Vigel-De Gracia P (2) 2020
  Wu Y 2020
Subtotal: I2=0.0%,P=0.98
Multiparity
  Chen L 2020
  Savasi V 2020
  Martinez-Perez O 2020
  Masmejan S 2020
Subtotal: I2=0.0%,P=0.92
Third trimester
  Yan J 2020
  Andrikopoulou M 2020
  Vigel-De Gracia P (2) 2020
Subtotal: I2=0.0%,P=0.80
Non-white
  Savasi V 2020
  Khoury R 2020
  Emeruwa U (1) 2020
  Menezes MO 2020
Subtotal: I2=34.7%,P=0.20
Any comorbidity
  Savasi V 2020
  Martinez-Perez O 2020
  Menezes MO 2020
Subtotal: I2=0.0%,P=0.73
Chronic hypertension
  Kayem G 2020
  Khoury R 2020
Subtotal: I2=0.0%,P=0.73
Pre-existing diabetes
  Kayem G 2020
  Khoury R 2020
  Menezes MO 2020
Subtotal: I2=0.0%,P=0.49
Pre-eclampsia
  Yan J 2020
  Martinez-Perez O 2020
  Brandt JS 2020
  Vigel-De Gracia P (2) 2020
Subtotal: I2=0.0%,P=0.61
Gestational diabetes
  Andrikopoulou M 2020
  Kayem G 2020
  Martinez-Perez O 2020




2.24 (1.50 to 3.35)
1.00 (0.13 to 7.46)
1.19 (0.65 to 2.18)
35.00 (1.07 to 1141.97)
1.52 (1.22 to 1.90)
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Fig 6 | risk factors associated with severe coronavirus disease 2019 (covid-19) in pregnant and recently pregnant women. symptom based 
screening: savasi v, Kayem g; nHcc (national Health commission china). criteria based screening: chen, wu, yan. all other studies used universal 
screening. cut-off for age is 35 years or more, and for body mass index is 30 or more. *includes one study with continuous measurement of risk 
factor
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to healthcare facilities, which could increase the risk of 
maternal and perinatal complications.98
Not many studies reported outcomes by trimester 
for symptom onset, making it difficult to assess the 
rates of miscarriage and postpartum complications. 
For some outcomes, the findings were influenced by a 
single large study.42 Many studies had to be excluded 
as we could not rule out potential overlap in the study 
populations. 
Areas of uncertainty in some of our review findings 
will still need to be resolved in the next updates of 
the living systematic review. In seeking an efficient 
balance between resource consumption and the 
value the review provides to end users, we will make 
table 2 | maternal characteristics associated with severe coronavirus disease 2019 (covid-19) and all cause death in pregnant and recently pregnant 
women with a diagnosis of covid-19
maternal risk factors  
and outcomes no of studies total no of women
Pregnant women (no with risk  
factor/no in group (%))
Odds ratio (95% ci) i2 (%)with outcome without outcome
Age ≥35 years:
 Severe disease 7 3561 811* 2750* 1.83 (1.27 to 2.63) 43
 ICU admission 7 31710 348* 31362* 2.11 (1.69 to 2.63) 0
 Invasive ventilation 3 718 18* 700* 1.72 (0.60 to 4.97) 17
 Maternal death 3 31710 176* 31525* 0.91 (0.22 to 3.72) 93
Multiparity:
 Severe disease 4 278 17/159 (10.7) 12/119 (10.1) 1.11 (0.50 to 2.46) 0
 ICU admission 3 815 34/501(6.8) 17/314 (5.4) 1.34 (0.72 to 2.50) 0
Invasive ventilation 1 350 1/216 (0.5) 0/134 (0) 1.87 (0.08 to 46.30) NE
Body mass index ≥30:
 Severe disease 5 3367 787* 2580* 2.37 (1.83 to 3.07) 0
 ICU admission 4 31456 339* 31117* 2.71 (1.10 to 6.63) 63
 Invasive ventilation 2 485 12* 4473* 6.61 (1.98 to 22.02) 0
 Maternal death 3 31085 113* 30972* 2.27 (1.20 to 4.31) 0
Non-white ethnicity:
 Severe disease 4 2263 375/1638 (22.9) 140/625 (22.4) 0.94 (0.57 to 1.57) 35
 ICU admission 4 31543 306/23996 (1.3) 158/7547 (2.1) 1.66 (1.20 to 2.29) 26
Invasive ventilation 1 669 20/134 (14.9) 39/535 (7.3) 2.23 (1.25 to 3.97) NE
 Maternal death 3 31 469 110/24 124 (0.5) 36/7345 (0.5) 1.61 (1.05 to 2.47) 0
Any comorbidity:
 Severe disease 3 2634 226/730 (31.0) 382/1904 (20.1) 1.81 (1.49 to 2.20) 0
 ICU admission 5 31 512 106/6639 (1.6) 226/24 873.9) 1.70 (1.34 to 2.15) 0
 Invasive ventilation 3 715 7/71 (9.9) 11/644(1.7) 5.26 (1.76 to 15.68) 0
 Maternal death 2 30 639 19/6493 (0.3) 33/24 146 (0.1) 2.53 (0.78 to 8.17) 50
Chronic hypertension:
 Severe disease 2 858 25/61 (41.0) 178/797 (22.3) 2.00 (1.14 to 3.48) 0
 ICU admission 5 31 433 15/262 (5.7) 319/31 171 (1.0) 4.72 (2.37 to 9.41) 13
 Invasive ventilation 2 484 5/24 (20.8) 7/460 (1.5) 63.82 (9.69 to 420.45) 0
 Maternal death 3 31 011 7/249 (2.8) 81/30 762 (0.3) 4.25 (1.82 to 9.95) 0
Pre-existing diabetes:
 Severe disease 3 3333 97/248 (39.1) 696/3085 (22.6) 2.12 (1.62 to 2.78) 0
 ICU admission 6 31 473 36/638 (5.6) 306/30 835 (1.0) 4.67 (1.94 to 11.22) 38
 Invasive ventilation 2 482 2/12 (16.7) 9/470 (1.9) 18.61 (0.26 to 1324.16) 78
 Maternal death 2 30 723 11/620 (1.8) 41/30 103 (0.1) 14.88 (4.19 to 52.81) 53
Asthma:
 Severe disease 4 3332 39/148 (26.4) 717/3184 (22.5) 1.43 (0.85 to 2.38) 28
 ICU admission 1 100 2/9 (22.2) 8/91 (8.8) 2.96 (0.53 to 16.74) NE
 Maternal death 3 889 5/39 (12.8) 63/850 (7.4) 1.68 (0.66 to 4.24) 0
Smoking:
 Severe disease 3 776 5/23 (21.7) 141/753 (18.7) 1.67 (0.64 to 4.40) 0
 ICU admission 2 142 1/4 (25.0) 17/138 (12.3) 2.92 (0.35 to 24.23) 0
 Maternal death 1 308 0/10 (0) 7/298 (2.3) 1.85 (0.10 to 34.60) NE
Gestation ≥28 weeks:
 Severe disease 3 289 29/227 (12.8) 16/62 (25.8) 0.56 (0.27 to 1.17) 0
 Maternal death 1 721 46/495 (9.3) 23/226 (10.2) 0.90 (0.53 to 1.53) NE
Gestational diabetes:
 Severe disease 4 973 18/88 (20.5) 148/885 (16.7) 1.23 (0.70 to 2.14) 0
 ICU admission 2 777 11/81 (13.6) 31/696 (4.5) 3.27 (1.55 to 6.89) 0
 Invasive ventilation 1 350 0/32 (0) 0/318 (0) — NE
Pre-eclampsia:
 Severe disease 4 274 4/16 (25.0) 18/258 (7.0) 4.21 (1.27 to 14.00) 0
 ICU admission 1 42 6/6 (100.0) 2/36 (5.6) 179.40 (7.69 to 4186.05) NE
ICU=intensive care unit; NE=not estimable.
*Includes one or more studies with continuous measurement of risk factor.
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decisions about the pacing of the updates of our 
living systematic review using a formal framework 
for decision making. We will use a mixed approach 
based on the Ottawa method to identify quantitative or 
qualitative signals for the need of an update,99 and a 
more complex statistical prediction tool to estimate the 
probability that new studies identified would change 
the review conclusions.100
comparison with existing evidence
Between the publication of the original living 
systematic review and this update, estimates for the 
prevalence of covid-19, and rates of clinical mani-
festations and outcomes of pregnant and recently 
pregnant women with covid-19 have remained similar, 
with improved precision in the findings. The rates 
for postpartum haemorrhage and admission to the 
neonatal unit appear to be slightly increased from the 
first version, while the rate of maternal pneumonia 
appears to be lower. High heterogeneity remains in 
the estimates for rates of clinical manifestations and 
outcomes.
We found that the same risk factors for severe covid-19 
identified in the original version of the living systematic 
review remained associated with severe covid-19 
with increased precision. Additional risk factors for 
severe disease, such as non-white ethnicity identified 
in this update, were also identified from large cohort 
studies such as the UK Obstetric Surveillance System 
and the US CDC surveillance report.42 101 Our findings 
are consistent with the reports of disproportionately 
high rates of severe covid-19 in non-pregnant ethnic 
minority populations,102 and in other areas of 
maternity care.103 104 The observed disparity could be 
attributed to associated comorbidities, socioeconomic 
characteristics, and factors related to access to and 
quality of care in the preconception, pregnancy, and 
postpartum periods.105 The multifaceted contributors 
to ethnic disparities need to be investigated to reduce 
mortality and morbidity related to both covid-19 and 
pregnancy.
Our review update also identified an increased risk 
for maternal death, need for maternal admission to the 
intensive care unit, and stillbirth in pregnant women 
with covid-19 compared to pregnant women without 
the disease. However, our confidence in these estimates 
is not high, owing to the small numbers of events in 
both groups. Further data are still needed to robustly 
assess these outcomes, along with the emerging data 
on increased risk of severe outcomes such as the need 
for ECMO.42
Alongside the spread of the pandemic, a shift has 
occurred in the types of studies published, with initial 
studies involving pregnant women from epidemic 
regions in China, followed by reports of large regional 
and national datasets from the US, UK, Netherlands, 
Spain, and, more recently, Latin American countries. 
The study design has also changed from initial small 
case series and case reports to large observational 
data, with recent studies also providing comparative 
data. 
The prevalence of covid-19 varied widely between 
studies, particularly when sampling was done based 
on symptoms or history of contact, highlighting the 
variations in criteria for testing. The current update 
includes 50 new studies from 11 additional countries 
on the prevalence of covid-19 in pregnancy. Despite the 
addition of five times more studies between the original 
version of our living systematic review and this update, 
from diverse populations globally, the prevalence of 
covid-19 in pregnant and recently pregnant women 
remains unchanged. Unlike the general population 
who are mostly tested for SARS-CoV-2 on the basis of 
symptoms or contact history, universal screening of all 
pregnant women attending the hospital for any reason 
could contribute to the consistency in the findings. 
However, the true prevalence of covid-19 in pregnancy 
is likely to be lower than the current estimate if all 
pregnant women, including those not attending the 
hospital are included.
In the recent cohort study of all individuals admitted 
with covid-19 in the UK, the cluster of respiratory 
symptoms of cough, fever, and breathlessness were 
observed in more than two thirds of individuals,106 
similar to reported rates in the US and China.107-109 But 
in our review, fewer pregnant and recently pregnant 
women with covid-19 manifested these symptoms 
than the non-pregnant population, indicating 
possible high rates of asymptomatic presentation in 
this population. This is likely because of the strategy 
of universal screening for covid-19 in pregnancy and 
the low thresholds for testing in pregnant women than 
in non-pregnant women. Despite the potential higher 
possibility of universal screening to detect pregnant 
women with mild disease, we observed an increase 
in admissions to the intensive care unit and need for 
invasive ventilation compared with non-pregnant 
women of reproductive age with covid-19. The findings 
were mainly influenced by the recently updated large 
Centers for Disease Control and Prevention report 
from the US,42 and a report from the Mexican General 
Directorate of Epidemiology registry.41
By accessing the unpublished data from our 
collaborators, we were able to include both women with 
and without symptoms from the US CDC surveillance 
data, in addition to the women with symptoms only who 
were included in the published report.42 Pregnancy 
status was not ascertained in a large proportion of 
women of reproductive age in the CDC report, which 
could affect the estimates. Furthermore, the outcomes 
for which the data were missing from the report were 
considered to be absent, potentially leading to bias. 
The report from the Mexican General Directorate of 
Epidemiology registry, available only as a preprint, 
included only women with symptoms who might be at 
high risk of complications. We recommend that studies 
comparing covid-19 related outcomes in pregnant 
versus non-pregnant women report the relevant 
estimates for both women with and without symptoms 
to avoid overestimation of the risk of complications 
due to selective reporting. The pooled estimates for 
severe covid-19 and admission to an intensive care 
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unit were, however, still relatively high in the non-
comparative data, indicative of a potential high risk in 
pregnancy. This is supported by the recent analysis in a 
Swedish study suggesting a high risk of admission to an 
intensive care unit and invasive ventilation in pregnant 
women compared to non-pregnant women.110
Similar to the general population, high body mass 
index and pre-existing comorbidity seemed to be risk 
factors for severity of covid-19 in pregnancy, including 
admission to an intensive care unit and invasive 
ventilation.106 Complications related to covid-19 did 
not seem to be increased in women presenting in 
the third trimester versus earlier in pregnancy or in 
multiparous versus primiparous women—but existing 
sample sizes are not large. Both chronic hypertension 
and pre-existing diabetes were associated with 
maternal death in pregnant women with covid-19, 
which are known risk factors in the general population. 
But it is not known if covid-19 was the direct cause of 
death for these women, and the numbers of studies 
are small. We observed an increase in rates of preterm 
birth in pregnant women with covid-19 compared 
with pregnant women without the disease. These 
preterm births could have been medically indicated, 
as the overall rates of spontaneous preterm births in 
pregnant women with covid-19 was broadly similar to 
those observed in the pre-pandemic period. Although 
about 50% of pregnant women underwent caesarean 
section in the non-comparative studies, we did not 
find a statistically significant difference in comparative 
studies of pregnant women with and without covid-19. 
The precision of the estimates is expected to improve 
with the publication of more data in the future. The 
overall rates of stillbirths and neonatal deaths do 
not seem to be higher than the background rates. 
The indications for admissions to the neonatal unit, 
observed in about a third of neonates delivered to 
mothers with covid-19, have not been reported. Local 
policies on observation and quarantine of infants with 
exposure to SARS-CoV-2 might have influenced these 
rates.
relevance for clinical practice and research
Based on existing data, healthcare professionals 
should be aware that pregnant and recently pregnant 
women with covid-19 might manifest fewer symptoms 
than the general population, with the overall pattern 
similar to that of the general population. Pregnant 
women should be informed of the increase in severity 
of covid-19 including admission to intensive care units, 
need for ECMO and invasive ventilation compared with 
non-pregnant women, and encouraged to undertake 
safety measures to reduce the risk of infection. 
Pregnant women with pre-existing comorbidities will 
need to be considered as a high risk group for covid-19, 
along with those who are obese and of older maternal 
age. Healthcare professionals need to be aware of 
the increased risk of severe covid-19 in pregnant and 
recently pregnant women of non-white ethnic origin, 
to plan close monitoring and have a low threshold 
for escalation of care. Clinicians will need to balance 
the need for regular multidisciplinary antenatal care 
to manage women with pre-existing comorbidities 
against unnecessary exposure to the virus, through 
virtual clinic appointments when possible. Pregnant 
women with covid-19 before term gestation might 
need to be managed in a unit with facilities to care for 
preterm neonates.
Further data are still needed to assess robustly if 
pregnancy related maternal and neonatal compli-
cations are increased in women with covid-19 
compared to pregnant women without the disease. 
Similarly, the association between pregnancy specific 
risk factors such as pre-eclampsia and gestational 
diabetes on covid-19 related outcomes needs further 
evaluation. Pre-eclampsia was reported to be asso-
ciated with severe covid-19 in small studies, but 
this requires further assessment as the clinical and 
laboratory presentation of severe pre-eclampsia could 
mimic worsening covid-19.111 Robust collection of 
maternal data by trimester of exposure, including the 
periconception period, is required to determine the 
effects of covid-19 on early pregnancy outcomes, fetal 
growth, and risk of miscarriage or stillbirth. We need 
detailed reporting of outcomes by ethnicity to quantify 
the risk of severe covid-19 in women from different 
ethnicities. Qualitative studies on behaviour and 
attitude to the pandemic can disentangle the relative 
importance of factors behind the ethnic disparities 
observed in the severity of covid-19.
Systematic reviews are considered to be the highest 
quality evidence informing guidelines, and poor 
quality reviews will have a direct impact on clinical 
care. Despite the urgent need for evidence on the 
impact of covid-19 in pregnant women, systematic 
reviews and meta-analyses still need to adhere to 
the reporting guidelines on search criteria, quality 
assessment, and analysis. This is particularly 
important as large numbers of non-peer reviewed 
scientific papers and reports are currently available 
in the public domain in multiple versions. Primary 
studies need to explicitly state if duplicate data have 
been included to avoid double counting of participants 
in evidence synthesis. Individual participant data 
meta-analysis of the emerging cohorts is critical to 
assess both differential presentation and outcomes 
by underlying risk factors, and to determine the 
differential effects of interventions to reduce the rates 
of complications. With the establishment of several 
national and global prospective cohorts, we expect the 
sample size of our meta-analysis to increase further in 
the coming months. Our living systematic review and 
meta-analysis with its regular search and analyses 
updates is ideally placed to assess the impact of new 
findings on the rapidly growing evidence base.
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